NervGen Pharma Corp Cash Flow Conversion Efficiency
NervGen Pharma Corp cash flow conversion efficiency. Based on the latest financial reports, NervGen Pharma Corp (NGEN) has a cash flow conversion efficiency ratio of 1.808x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.32 Million ≈ $-3.85 Million USD) by net assets (CA$-2.94 Million ≈ $-2.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NervGen Pharma Corp (2017–2024)
Cash flow conversion efficiency of NervGen Pharma Corp from 2017 to 2024. This chart illustrates how NervGen Pharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NervGen Pharma Corp stock quote for real-time trading data and today's change.
NervGen Pharma Corp Cash Flow Conversion Ratio Explained
NervGen Pharma Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NervGen Pharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NervGen Pharma Corp ranked by their cash flow conversion efficiency. Also see market cap of NervGen Pharma Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iron Horse Acquisitions II Corp. Common Stock
NASDAQ:IRHO
|
-0.003x |
|
Eimskipafélag Íslands hf
IC:EIM
|
0.017x |
|
Advancetek Enterprise Co Ltd
TW:1442
|
-0.019x |
|
Sprott Focus Trust
NASDAQ:FUND
|
N/A |
|
Shanghai CEO Environmental Protection Technology Co Ltd
SHG:688335
|
0.013x |
|
Orizon Valorização de Resíduos S.A
SA:ORVR3
|
0.002x |
|
JCY International Bhd
KLSE:5161
|
-0.028x |
|
Asia Cement (China) Holdings Corporation
F:4OJ
|
0.017x |
Annual Cash Flow Conversion Efficiency for NervGen Pharma Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of NervGen Pharma Corp from 2017 to 2024. Review NervGen Pharma Corp free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$2.58 Million ≈ $1.86 Million |
CA$-16.84 Million ≈ $-12.18 Million |
-6.536x | -216.26% |
| 2023-12-31 | CA$-2.01 Million ≈ $-1.45 Million |
CA$-11.30 Million ≈ $-8.17 Million |
5.622x | +525.55% |
| 2022-12-31 | CA$13.46 Million ≈ $9.74 Million |
CA$-17.78 Million ≈ $-12.86 Million |
-1.321x | -168.70% |
| 2021-12-31 | CA$16.82 Million ≈ $12.17 Million |
CA$-8.27 Million ≈ $-5.98 Million |
-0.492x | +53.85% |
| 2020-12-31 | CA$5.92 Million ≈ $4.28 Million |
CA$-6.31 Million ≈ $-4.56 Million |
-1.065x | +23.12% |
| 2019-12-31 | CA$5.84 Million ≈ $4.23 Million |
CA$-8.09 Million ≈ $-5.86 Million |
-1.386x | -234.95% |
| 2018-12-31 | CA$2.51 Million ≈ $1.82 Million |
CA$-1.04 Million ≈ $-752.38K |
-0.414x | -100.47% |
| 2017-12-31 | CA$-11.81K ≈ $-8.55K |
CA$-1.04 Million ≈ $-752.38K |
88.045x | -- |
About NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more